Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

BACKGROUND: Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Charles J, Dutta, Sandipan, Kelly, William K, Russell, Carly, Small, Eric J., Morris, Michael J., Taplin, Mary-Ellen, Halabi, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825875/
https://www.ncbi.nlm.nih.gov/pubmed/31053766
http://dx.doi.org/10.1038/s41391-019-0152-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825875/
https://www.ncbi.nlm.nih.gov/pubmed/31053766
http://dx.doi.org/10.1038/s41391-019-0152-3

Ejemplares similares